Eledon Pharmaceuticals, Inc. - Common Stock (ELDN)
2.0600
-2.0400 (-49.76%)
NASDAQ · Last Trade: Nov 8th, 11:23 AM EST
Detailed Quote
Previous Close
4.100
Open
2.000
Bid
2.000
Ask
2.100
Day's Range
1.430 - 2.150
52 Week Range
1.430 - 5.170
Volume
29,781,212
Market Cap
46.36M
PE Ratio (TTM)
14.71
EPS (TTM)
0.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,013,723
Chart
About Eledon Pharmaceuticals, Inc. - Common Stock (ELDN)
Eledon Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for the treatment of serious diseases through advancing the understanding of the immune system. The company is primarily engaged in creating and commercializing novel therapeutics that aim to enhance immune responses, with a strong emphasis on addressing unmet medical needs in areas such as neuromuscular and autoimmune disorders. By leveraging its proprietary platform, Eledon seeks to provide groundbreaking solutions that improve patient outcomes and transform healthcare in the specialties it targets. Read More
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
Eledon shares drop as tegoprubart misses the main goal in Phase 2 kidney transplant trial, though safety signals and kidney function data remain encouraging.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m²
IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will present at the upcoming Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025, at 10:30 a.m. ET (7:30 a.m. PT).
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upcoming 18th Congress of the International Xenotransplantation Association (IXA) taking place from September 30–October 3, 2025, in Geneva, Switzerland.
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Friday, September 5, 2025, at 9:10 a.m. ET (6:10 a.m. PT).
Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation. These data, from approximately 30 kidney transplant recipients, are being presented at the World Transplant Congress (WTC) in San Francisco, CA on August 6, 2025.
IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation will be presented at the World Transplant Congress (WTC) taking place in San Francisco from August 2-6, 2025. The oral presentation will feature updated results from approximately 30 kidney transplant recipients and will be presented by Dr. John Gill from the University of British Columbia.
